Eating

GLP-1 Price Tracker: List Prices, Self-Pay Programs and Savings Cards, Updated Monthly

Jeff Zorn · · 15 min read

Share

By Jeff Zorn, founder of Zornava. Former college basketball player, degree in exercise science and nutrition, two years on GLP-1 medications. My experience, not medical advice. Talk to your prescriber or a registered dietitian about your own situation.

Published · Last reviewed

Short answer: as of November 13, 2026, list prices for the main GLP-1 brands run from $1,028 to $1,349 a month, but the makers' own cash prices are far lower: $299 to $449 for Zepbound vials or KwikPens through LillyDirect, $349 for the Wegovy injection up to 2.4 mg and $349 to $499 for the Ozempic pen.[1][2][3][4] Cash prices have fallen in steps since 2024: Lilly's 2.5 mg Zepbound vial went from $399 at launch in August 2024 to $299 in December 2025.[5][6] Novo Nordisk cuts the list price of Wegovy, Ozempic and Rybelsus to $675 on January 1, 2027.[7]

New to eating less? Start with what to eat when you're eating less, the guide the rest of Lighter Days builds on.

This page is a data set, not a guide. It holds two tables: every FDA-approved GLP-1 product and form with its list price, the maker's cash price by dose, the savings-card terms and the Medicare route, and a dated log of every price change since 2023 that we could source. Both are free to reuse with credit, and both download as CSV. If you want to know how to pay less, read our explainer, GLP-1 cost without insurance, which walks through coverage, appeals and the legal ways to lower the bill. What each medicine is and does is on our map of GLP-1 medications.

General information, not medical or financial advice. Every figure is "as of November 13, 2026", is cited to the maker, a government page or a named report, and is rechecked monthly. Check the maker's page and your plan before you rely on any of it.

GLP-1 prices by product and form (as of November 13, 2026)

One row per product and form. "List" is the maker's wholesale acquisition cost (WAC) for about a month's supply, before rebates. "Cash" is the maker's own self-pay price with a prescription. Savings cards apply to commercial insurance only. All rows checked November 13, 2026.
Product and form Maker List price (WAC), a month Maker's cash price, by dose Savings card (commercial insurance only) Medicare route Source Checked
Zepbound single-dose pen Lilly $1,087 Not sold as self-pay; see the next row As little as $25 if the plan covers it; as low as $499 if it does not. Ends December 31, 2026 GLP-1 Bridge: no more than $50 a month if eligible [1][2] Nov 13, 2026
Zepbound vials and KwikPen (LillyDirect self-pay) Lilly None; sold only through the self-pay channel 2.5 mg $299; 5 mg $399; 7.5–15 mg $449 with each refill within 45 days. Otherwise KwikPen 7.5 mg $499, 10–15 mg $699 Cash only; cannot be billed to insurance Self-pay offer not for government beneficiaries; CMS's BALANCE model names the Zepbound KwikPen [2][8][9] Nov 13, 2026
Mounjaro pen Lilly $1,080 (2025) No self-pay price published As little as $25 if covered; as low as $499 if not. Ends December 31, 2026 Part D covers it for type 2 diabetes; Lilly says about 8 in 10 pay $0 to $50 for 28 days [10][11] Nov 13, 2026
Wegovy injection (pen) Novo Nordisk $1,349; $675 from January 1, 2027 0.25–2.4 mg $349; 7.2 mg $399. New patients: $199 for the first two fills of 0.25 or 0.5 mg, through December 31, 2026 As little as $25, up to $100 a month in savings GLP-1 Bridge: $50 a month if eligible [1][7][3][12] Nov 13, 2026
Wegovy pill Novo Nordisk $1,349 1.5 mg $149; 4 mg $199; 9 or 25 mg $299 As little as $25, up to $100 a month in savings CMS's BALANCE model names Wegovy [1][3][9] Nov 13, 2026
Ozempic pen Novo Nordisk $1,028; $675 from January 1, 2027 0.25, 0.5 or 1 mg $349; 2 mg $499. New patients: $199 for two fills of 0.25 or 0.5 mg As little as $25, up to $100 a month; not for Medicare or Medicaid enrollees Part D plans cover diabetes drugs; plan copays vary [1][7][4] Nov 13, 2026
Ozempic tablets Novo Nordisk Not published on the pages we checked 1.5 mg $149; 4 mg $199; 9 mg $299 As little as $25 Plan copays vary [4] Nov 13, 2026
Rybelsus tablets Novo Nordisk $998 for 30 tablets (2025); $675 from January 1, 2027 Not published on the pages we checked Check the maker's page CMS's BALANCE model names Rybelsus; plan copays vary [10][7][9] Nov 13, 2026
Foundayo (orforglipron) pill Lilly Not published on the pages we could read From $149 for the lowest dose; $349 reported for the highest. TrumpRx lists 2.5 mg $199 and 5.5 mg $299 As little as $25 if covered Announced at $50 a month from as soon as July 1, 2026; named in CMS's BALANCE model [13][14][15][9] Nov 13, 2026
Saxenda pen, and generic liraglutide Novo Nordisk; generic from Teva $1,349.02 (brand) None. Saxenda is being discontinued, last shipments to wholesalers late January 2027 None; the offer closed to new enrollees on June 30, 2023 Part D cannot cover drugs for obesity alone [16][17][18] Nov 13, 2026
Victoza pen, and generic liraglutide Novo Nordisk; first generic from Hikma $815 for 3 pens (2025) Not published on the pages we checked; first generic approved December 23, 2024 Check the maker's page Plan copays vary [10][19] Nov 13, 2026
Trulicity pen Lilly $987 for 4 pens (2025) From $389 a month at each dose (0.75, 1.5, 3 and 4.5 mg) through LillyDirect Check the maker's page Plan copays vary [10][20] Nov 13, 2026

Where the list prices come from: Zepbound, Wegovy and Ozempic use the "original price" on the federal TrumpRx site; Mounjaro, Rybelsus, Victoza and Trulicity use 2025 wholesale prices per 30-day supply from an Oregon state affordability study, which takes them from the Medi-Span database; Saxenda's is from trade press.[1][10][16] Novo Nordisk said its January 2027 list price cut does not change its self-pay prices, and says its self-pay prices will be updated after December 31, 2026.[7][3] Compounded copies are not FDA-approved and are not in the table.

What is the cheapest GLP-1 without insurance?

On the makers' published cash prices, the lowest monthly figure is $149, for the lowest strength of the Wegovy pill or Ozempic tablets and for Foundayo's lowest dose.[3][4][13] Those are starting strengths; the price rises with the dose. For injections, the lowest is Lilly's 2.5 mg Zepbound vial at $299, but the label says 2.5 mg "is for treatment initiation and is not approved as a maintenance dosage."[2][21] On maintenance doses, the cash prices cluster between $349 and $449 a month.[2][3] Which medicine and dose fit is your prescriber's decision, not a price decision.

How have GLP-1 prices changed since 2023?

List prices have stayed close to their launch levels; cash prices have fallen in steps. Zepbound launched in November 2023 at a list price of $1,059.87 a month,[22] and Wegovy in June 2021 at $1,297.[23] Since August 2024, both makers have opened direct cash channels and cut them several times. The first list price cut of this kind takes effect on January 1, 2027.[7]

GLP-1 price changes, 2021 to 2027, by date. "Scheduled" rows are announced and not yet in effect as of November 13, 2026.
Date Product Change Source
June 2021 Wegovy injection Launched at a list price of $1,297 a month (baseline) [23]
June 30, 2023 Saxenda Savings offer closed to new enrollees [17]
November 8, 2023 Zepbound pen FDA approval; launch list price $1,059.87 a month [22]
August 27, 2024 Zepbound vials Lilly launched single-dose vials for self-pay through LillyDirect: 2.5 mg $399 and 5 mg $549 for four weeks [5]
December 23, 2024 Victoza (liraglutide) FDA approved the first generic [19]
February 25, 2025 Zepbound vials 2.5 mg cut to $349 and 5 mg to $499; 7.5 mg and 10 mg vials added at $499 with refills within 45 days, down from $599 and $699 [24]
March 5, 2025 Wegovy injection Novo launched NovoCare Pharmacy: every pen dose $499 a month for cash buyers, down from a $650 direct-ship option [25]
June 16, 2025 Zepbound vials 12.5 mg and 15 mg vials added at $499 a month, so every dose was available as a vial [26]
August 28, 2025 (reported) Saxenda (liraglutide) Teva's generic approved and launched; brand list price $1,349.02 [16]
November 6, 2025 Zepbound, Wegovy, Ozempic, Mounjaro White House agreements with Lilly and Novo: TrumpRx averages of $346 (Zepbound) and $350 (Ozempic, Wegovy); a $245 Medicare price with a $50 copay for eligible beneficiaries [27][28]
November 17, 2025 Wegovy injection, Ozempic pen Self-pay price cut by $150 to $349 a month; $199 for the first two months of 0.25 or 0.5 mg for new self-pay patients, then announced through March 31, 2026 [29]
December 1, 2025 Zepbound vials Cut to $299 (2.5 mg), $399 (5 mg) and $449 (higher doses) a month [6]
January 5, 2026 Wegovy pill Launched from $149 a month for cash buyers; $299 for 9 mg and 25 mg [30]
February 5, 2026 All listed brands TrumpRx.gov launched, a federal site listing the cash prices [31]
February 24, 2026 Wegovy, Ozempic, Rybelsus Novo announced a list price cut to $675 a month from January 1, 2027, about 50% off Wegovy and 35% off Ozempic; self-pay prices unchanged [7]
April 1, 2026 Foundayo FDA approval; self-pay from $149 a month for the lowest dose, and $50 a month on Medicare announced from as soon as July 1, 2026 [32][13]
July 1, 2026 Certain GLP-1s on Medicare Part D Medicare GLP-1 Bridge began: $50 copay with prior authorization, through December 31, 2027 [12]
November 13, 2026 (as checked) Wegovy injection, Ozempic pen Maker's pages list the $199 new-patient offer through December 31, 2026, later than the March 31, 2026 end first announced; the date of the extension is not stated [3][4]
December 31, 2026 (scheduled) Zepbound, Mounjaro Lilly's savings cards end [2][11]
January 1, 2027 (scheduled) Wegovy, Ozempic, Rybelsus List price falls to $675 a month [7]
Late January 2027 (scheduled) Saxenda Last shipments to wholesalers before discontinuation, not for safety or quality reasons [17]

Read the log as two separate stories. The cash price for a starting dose of Zepbound fell by a quarter, from $399 to $299, in 15 months,[5][6] and Novo's cash price for the Wegovy injection fell from $499 in March 2025, itself down from a $650 direct-ship option, to $349 in November 2025.[25][29] The list price, which drives what insured people pay under a deductible or coinsurance, stayed near $1,000 to $1,350 throughout, and the January 2027 cut is the first large one we found.[1][7]

How we check these prices every month

Once a month, and whenever a maker announces a change, we reopen every source in the tables: the makers' price and savings pages (LillyDirect and the Zepbound, Mounjaro and Trulicity pages; NovoCare and the Wegovy, Ozempic and Saxenda pages), TrumpRx.gov, and the CMS pages for the GLP-1 Bridge and the BALANCE model.[2][3][1][12][9] A figure that has changed is updated in the first table, and the change goes into the log with its date and source. The "as of" date moves only when every row has been rechecked on that day.

What each column means:

  • List price (WAC): the maker's price to wholesalers for about a month's supply, before rebates and discounts. Few people pay it, but it is the base for deductibles and coinsurance. Where a maker or TrumpRx does not publish it, we use the most recent figure from a public state study and give the year.
  • Maker's cash price: what the maker itself charges a person paying out of pocket with a valid prescription, through its own pharmacy channel or a self-pay offer at retail. It usually does not count toward an insurance deductible.[3][33]
  • Savings card: the maker's copay program for people with commercial insurance. Cards have monthly or yearly caps and exclude Medicare, Medicaid and other government coverage.[2][4]
  • Medicare route: how a Part D enrollee can get the drug. Part D is barred by law from covering drugs for obesity alone; the GLP-1 Bridge is the exception from July 1, 2026.[18][12]

What we leave out: compounded drugs, telehealth and pharmacy membership prices, coupon-site prices and prices outside the US. Compounded semaglutide and tirzepatide are not FDA-approved, and the FDA does not check compounded drugs before they are sold;[34] the reasons are set out in compounded GLP-1s explained. Prices are in US dollars as published, not adjusted for inflation. Spotted an out-of-date figure? Tell us through our contact page and we will recheck it.

Download the data and how to cite it

Both tables are free to reuse under a CC BY 4.0 license, as long as you keep the credit line "Source: Zornava, zornava.com". Each CSV is UTF-8 with a header row and a source URL for every row.

How to cite this tracker

APA: Zornava. (2026). GLP-1 price tracker: List prices, self-pay programs and savings cards [Data set]. Retrieved November 13, 2026, from https://zornava.com/blogs/lighter-days/glp-1-price-tracker

Plain text: Zornava, "GLP-1 price tracker: list prices, self-pay programs and savings cards," zornava.com, updated November 13, 2026, https://zornava.com/blogs/lighter-days/glp-1-price-tracker (accessed November 13, 2026).

Credit line for reused data: Source: Zornava, zornava.com. CC BY 4.0.

Related pages

For transparency about why this page exists on our site: we make one product, Zornava Replenish, a lemon-lime daily hydration and nutrient powder for lighter appetite days, including for people on GLP-1 medications. It is a dietary supplement, not a medication, and it does not replace or imitate any medicine on this page. It is not on sale yet; early access opens February 9, 2027, and the early-access list is open now.

Frequently asked questions

How much do GLP-1 medications cost a month?

As of November 13, 2026, list prices for the main brands run from $1,028 (Ozempic) to $1,349 (Wegovy) a month. The makers' cash prices are lower: $299 to $449 for Zepbound vials or KwikPens with on-time refills, $349 for the Wegovy injection up to 2.4 mg, $349 to $499 for the Ozempic pen, and $149 to $299 for the Wegovy pill.

What is the difference between the list price and the cash price?

The list price, or wholesale acquisition cost, is what the maker charges wholesalers before rebates. It matters to insured people because deductibles and coinsurance are based on it. The cash price is the maker's separate, lower price for someone paying out of pocket with a prescription, and it usually does not count toward a deductible.

Which GLP-1 is cheapest without insurance?

The lowest published maker cash price is $149 a month, for the lowest strength of the Wegovy pill or Ozempic tablets and for Foundayo's lowest dose. Those are starting strengths and the price rises with the dose. Among injections, Zepbound 2.5 mg vials are $299, but 2.5 mg is a starting dose; maintenance doses cost $349 to $449 a month.

Have GLP-1 prices gone down?

Cash prices have. Lilly's 2.5 mg Zepbound vial went from $399 in August 2024 to $299 in December 2025, and Novo's cash price for the Wegovy injection went from $650 to $499 in March 2025 and to $349 in November 2025. List prices stayed near $1,000 to $1,350 a month until Novo's cut to $675 for Wegovy, Ozempic and Rybelsus, effective January 1, 2027.

Can people on Medicare use the makers' savings cards?

No. Lilly's and Novo Nordisk's savings cards exclude Medicare, Medicaid and other government coverage. Medicare Part D covers GLP-1s prescribed for type 2 diabetes, and from July 1, 2026 to December 31, 2027 the Medicare GLP-1 Bridge offers certain GLP-1s for weight management at a $50 copay, with prior authorization.

How often is this tracker updated, and can I reuse the data?

We recheck every row once a month and whenever a maker announces a change, and log each change with its date and source. The data is free to reuse under CC BY 4.0 with the credit line "Source: Zornava, zornava.com", and both tables download as CSV.

References

  1. US Department of Health and Human Services. TrumpRx.gov. TrumpRx.gov. 2026. trumprx.gov. Federal price listing read 2026-11-13: "Lowest Presidential Deal" and "Original Price" per month for Wegovy pill ($149; $1,349), Wegovy pen ($199; $1,349), Ozempic ($199; $1,028) and Zepbound ($299; $1,087). ↩︎
  2. Eli Lilly and Company. Zepbound coverage and savings. zepbound.lilly.com. 2026. (self-pay and savings card terms) zepbound.lilly.com. Maker price page and offer terms read 2026-11-13; savings card terms end 2026-12-31. ↩︎
  3. Novo Nordisk. Wegovy savings offer and self-pay pricing. NovoCare. 2026. (self-pay prices and offer terms) novocare.com. Maker price page read 2026-11-13; prices stated to be updated after 2026-12-31. ↩︎
  4. Novo Nordisk. Save on Ozempic. ozempic.com. 2026. ozempic.com. Maker price page read 2026-11-13. ↩︎
  5. Tracy D (Pharmaceutical Executive). Lilly Introduces Single-Dose Vials of Zepbound, Expanding Access for Adults with Obesity. Pharmaceutical Executive. 2024. pharmexec.com. Trade-press report of 2024-08-27 on Lilly's launch of Zepbound single-dose vials through LillyDirect: 2.5 mg $399 and 5 mg $549 for a four-week supply (Lilly's own release refuses scripted requests). Secondary. ↩︎
  6. Pharmaceutical Executive. Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients. Pharmaceutical Executive. 2025. pharmexec.com. Trade-press report of 2025-12-01 on Lilly's LillyDirect vial prices (Lilly's own pages refuse scripted requests). ↩︎
  7. Novo Nordisk. Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus (semaglutide medicines), building on continued efforts to expand access. Press release (PR Newswire, via BioSpace). 2026. biospace.com. Press release of 2026-02-24. List price change effective 2027-01-01. ↩︎
  8. Eli Lilly and Company. How do I get Zepbound (tirzepatide) vials or multi-dose KwikPens? Lilly Medical (medical.lilly.com). 2026. medical.lilly.com. Maker medical-information page; date of last review 2026-02-23. ↩︎
  9. Centers for Medicare & Medicaid Services. BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model. cms.gov. 2026. cms.gov. Page read (last modified 2026-09-29). ↩︎
  10. Oregon Prescription Drug Affordability Board (Department of Consumer and Business Services). Mounjaro (tirzepatide) affordability review, version 4.0. dfr.oregon.gov. 2026. (Table 12, WAC per 30-day supply, 2025) dfr.oregon.gov. State review dated 2026-09-14. Table 12 gives 2019–2025 wholesale acquisition cost per 30-day supply for Mounjaro and its alternatives (Ozempic, Rybelsus, Trulicity, Victoza, Byetta), from Medi-Span. ↩︎
  11. Eli Lilly and Company. Mounjaro savings and resources. mounjaro.lilly.com. 2026. mounjaro.lilly.com. Maker price page read 2026-11-13: $25 for up to a 3-month fill with commercial coverage; as low as $499 for a 1-month single-dose pen fill with commercial insurance that does not cover it; card expires 2026-12-31; not for Medicare/Medicaid enrollees; about 8 in 10 Medicare patients pay $0-$50 per 28-day supply (IQVIA Oct 2024-Sep 2025). No self-pay price listed. ↩︎
  12. Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge. cms.gov. 2026. cms.gov. Page read (last modified 2026-07-13). ↩︎
  13. Eli Lilly and Company. Press release (PR Newswire, via BioSpace). 2026. biospace.com. Press release of 2026-04-01. Company statements on pricing and access. ↩︎
  14. Vinluan F (MedCity News). Eli Lilly Gets Speedy FDA Nod for Oral GLP-1 Drug, a Competitor to New Novo Nordisk Pill. MedCity News. 2026. medcitynews.com. News report of 2026-04-01; the $349 highest-dose price is attributed to a UBS analyst note. ↩︎
  15. US Department of Health and Human Services. Foundayo. TrumpRx.gov. 2026. trumprx.gov. Federal price listing read 2026-11-13; 2.5 mg and 5.5 mg temporarily reduced through 2026-12-31 (reduced amounts not shown). ↩︎
  16. Managed Healthcare Executive. Teva launches first generic GLP-1 drug for obesity. Managed Healthcare Executive. 2025. managedhealthcareexecutive.com. Trade-press report of 2025-08-28 on Teva's FDA approval and launch of generic Saxenda (liraglutide); source for Saxenda's $1,349.02 list price. The generic's price is not stated. Secondary. ↩︎
  17. Novo Nordisk. Saxenda: savings and support. novocare.com. 2026. novocare.com. Maker page read 2026-11-13: savings offer closed to new enrollees 2023-06-30; advance notice that Saxenda will be discontinued, last shipments to wholesalers late January 2027, not for safety or quality reasons. ↩︎
  18. KFF. Medicaid Coverage of and Spending on GLP-1s. kff.org. 2026. kff.org. Analysis of 2026-01-16. ↩︎
  19. US Food and Drug Administration. FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes. fda.gov. 2024. fda.gov. Press announcement of 2024-12-23 (generic Victoza, liraglutide 18 mg/3 mL, Hikma). ↩︎
  20. Eli Lilly and Company. Trulicity (dulaglutide) through LillyDirect. lilly.com. 2026. lilly.com. Maker self-pay page read 2026-11-13: starting at $389 a month for each of the 0.75, 1.5, 3 and 4.5 mg doses; prescription required. ↩︎
  21. Eli Lilly and Company. Zepbound (tirzepatide) injection, prescribing information and Medication Guide. DailyMed, US National Library of Medicine. 2026. (section 2) DailyMed. ↩︎
  22. CNBC. CNBC. 2023. cnbc.com. News report of 2023-11-08; launch list price cross-checked against BioSpace. ↩︎
  23. Healthcare Dive. Novo keeps price in line with FDA approval of second obesity shot. Healthcare Dive. 2021. healthcaredive.com. News report of 2021-06-07 (BioPharma Dive). ↩︎
  24. Pharmacy Times. New Pricing, Access to Tirzepatide Available Through Self-Pay Options. Pharmacy Times. 2025. pharmacytimes.com. Trade-press report of 2025-02-26 on Lilly's 2025-02-25 release: 7.5 mg and 10 mg vials $499 (from $599 and $699) at first fill and on-time refills; 2.5 mg $349, 5 mg $499. Secondary. ↩︎
  25. Managed Healthcare Executive. Novo Nordisk Lowers Wegovy Price for Cash-Paying Patients. Managed Healthcare Executive. 2025. managedhealthcareexecutive.com. Trade-press report of 2025-03-05 on the NovoCare Pharmacy launch: all Wegovy pen strengths (0.25 to 2.4 mg) $499 a month for cash payers, replacing a $650 direct-ship option. Secondary. ↩︎
  26. Pharmaceutical Executive. Lilly Launches Full Zepbound Dose Access for Obesity Through LillyDirect Self-Pay Program. Pharmaceutical Executive. 2025. pharmexec.com. Trade-press report of 2025-06-16: 12.5 mg and 15 mg vials at $499 a month; 2.5 mg $349. Secondary. ↩︎
  27. The White House. Fact Sheet: President Donald J. Trump Announces Major Developments in Bringing Most-Favored-Nation Pricing to American Patients. whitehouse.gov. 2025. whitehouse.gov. Fact sheet of 2025-11-06. Announced prices; what has taken effect is cited separately. ↩︎
  28. Eli Lilly and Company. Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans. Press release (PR Newswire, via BioSpace). 2025. biospace.com. Press release of 2025-11-06. Does not mention retatrutide. ↩︎
  29. Pharmaceutical Executive. Novo Nordisk Rolls Out $199 Intro Offer for Wegovy and Ozempic, Months Ahead of Planned Price Cuts. Pharmaceutical Executive. 2025. pharmexec.com. Trade-press report of 2025-11-18 on Novo's 2025-11-17 announcement: regular self-pay price $349 a month (down $150); $199 for the first two months of 0.25 or 0.5 mg for new self-pay patients until 2026-03-31. Secondary. ↩︎
  30. pharmaphorum. Novo Nordisk launches Wegovy pill at $149 a month. pharmaphorum. 2026. pharmaphorum.com. Trade-press report of 2026-01-05. ↩︎
  31. The White House. Fact Sheet: President Donald J. Trump Launches TrumpRx.gov to Bring Lower Drug Prices to American Patients. whitehouse.gov. 2026. whitehouse.gov. Fact sheet of 2026-02-05. ↩︎
  32. US Food and Drug Administration. FDA Approves First New Molecular Entity Under National Priority Voucher Program. fda.gov. 2026. fda.gov. Press announcement of 2026-04-01. ↩︎
  33. KFF. TrumpRx: What's the Value for Customers? kff.org. 2026. kff.org. Analysis of 2026-02-24. ↩︎
  34. US Food and Drug Administration. Compounding and the FDA: Questions and Answers. fda.gov. 2025. fda.gov. Page read (content current as of 09/16/2025). ↩︎
Share this
← All Lighter Days articles

Free guide

The GLP-1 eating plan

Eight pages to print and keep, built protein first for days when appetite is small. Sourced, like everything on Lighter Days.

  • Seven days of four small meals, with protein and fiber counted
  • A food list: what to eat more often, and what to go easy on
  • A shopping list and a page to take to your prescriber or dietitian

You’ll also get early access to Replenish and a few emails a month. Unsubscribe any time.